GLP-1 Therapies Show Promise for Improving Limb Outcomes in Peripheral Artery Disease

Peripheral Artery Disease (PAD) is a chronic circulatory condition where narrowed arteries reduce blood flow to the limbs, most commonly the legs. This can lead to severe complications like non-healing wounds, pain, and ultimately, limb amputation, significantly impacting patient quality of life and increasing mortality. Patients with PAD often have co-existing metabolic conditions such as type 2 diabetes, for which GLP-1 receptor agonists are a cornerstone treatment. Despite their established cardiovascular benefits, the specific impact of these therapies on limb-specific outcomes in patients with PAD in real-world settings has remained less clear.

The meta-analysis revealed a significant protective effect of GLP-1-based therapies on limb outcomes in patients with PAD. Treatment with GLP-1 receptor agonists was associated with a 28% reduction in the risk of major adverse limb events (MALE) compared to control groups (Hazard Ratio 0.72, 95% CI 0.65-0.80, p<0.001). Specifically, there was a 35% lower risk of major amputations (HR 0.65, 95% CI 0.54-0.78, p<0.001) and a 22% reduction in the need for limb revascularization procedures (HR 0.78, 95% CI 0.70-0.87, p<0.001). The most impactful finding was a 43% reduction in the composite endpoint of critical limb ischemia-related hospitalizations or death due to limb complications (HR 0.57, 95% CI 0.48-0.68, p<0.001). These benefits were observed consistently across different GLP-1 receptor agonists and patient populations, highlighting a robust effect.